Q16L (p.Gln16Leu) variant of TP53 (Cellular tumor antigen p53)
Q16L (p.Gln16Leu) in TP53 (Cellular tumor antigen p53) is a missense change. Clinical records from EBI and UniProt describe it as uncertain significance in the context of in a sporadic cancer. The available variant effect predictions contribute to a CATVariant prioritization score of 0.22 / 1. The record also includes experimental measurements and structural context.
Q16L (p.Gln16Leu) variant details
- p.Gln16Leu
- cosmic curated COSV53100
- UniProt VAR 044550
- Uncertain significance
- in a sporadic cancer
- Missense
- Variant Prioritization Score for Impact Estimate 0.223
- ESM-1b 0.00
- AlphaMissense 0.55
- EBI: Variant of uncertain significance (in a sporadic cancer)
- UniProt: Uncertain significance (in a sporadic cancer)
- Structural context available
- p53 variant effect measured by cell growth: score -3.51